Retinal vein thrombosis: Pathogenesis and management: Reply to a rebuttal

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 2, 2011, Pages 419-420

  Rehak, M ^a   Wiedemann, P ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; PARNAPARIN; PLACEBO;

HUMAN; LETTER; META ANALYSIS (TOPIC); PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA VEIN OCCLUSION; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION;

EID: 79251572375     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04145.x     Document Type: Letter

References (3)

1. Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 2010; 8: 1886-94.
2. Squizzato A, Manfredi E, Bozzato S, Dentali F, Ageno W. Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action. Thromb Haemost 2010; 103: 271-6.
3. Lazo-Langner A, Hawell J, Ageno W, Kovacs MJ. Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. Haematologica 2010; 95: 1587-93.